KR101919080B1 - 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 - Google Patents
디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 Download PDFInfo
- Publication number
- KR101919080B1 KR101919080B1 KR1020137033509A KR20137033509A KR101919080B1 KR 101919080 B1 KR101919080 B1 KR 101919080B1 KR 1020137033509 A KR1020137033509 A KR 1020137033509A KR 20137033509 A KR20137033509 A KR 20137033509A KR 101919080 B1 KR101919080 B1 KR 101919080B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrimido
- oxazepin
- alkyl
- mmol
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC[n](ccc1c2)c1ccc2N(CCO1)C2=*c3c2c1ncn3 Chemical compound CCC[n](ccc1c2)c1ccc2N(CCO1)C2=*c3c2c1ncn3 0.000 description 4
- RQUBNSLOMNELFS-UHFFFAOYSA-N O=C1c(c(Cl)ncn2)c2OCCC1c(cc(cc[n]1-c2ccccc2)c1c1)c1F Chemical compound O=C1c(c(Cl)ncn2)c2OCCC1c(cc(cc[n]1-c2ccccc2)c1c1)c1F RQUBNSLOMNELFS-UHFFFAOYSA-N 0.000 description 2
- OKSDEMCTIKXXIW-UHFFFAOYSA-N Oc(cc(cc[n]1-c2ccccc2)c1c1)c1F Chemical compound Oc(cc(cc[n]1-c2ccccc2)c1c1)c1F OKSDEMCTIKXXIW-UHFFFAOYSA-N 0.000 description 2
- XGMVTXUXZUPGGY-UHFFFAOYSA-N COc(c(F)c1)ccc1[N+]([O-])=O Chemical compound COc(c(F)c1)ccc1[N+]([O-])=O XGMVTXUXZUPGGY-UHFFFAOYSA-N 0.000 description 1
- RNAYQVUKHRPRMO-UHFFFAOYSA-N COc(cc(CC#N)c([N+]([O-])=O)c1)c1F Chemical compound COc(cc(CC#N)c([N+]([O-])=O)c1)c1F RNAYQVUKHRPRMO-UHFFFAOYSA-N 0.000 description 1
- DANYGEQACAPBOK-UHFFFAOYSA-N COc(cc(cc[nH]1)c1c1)c1F Chemical compound COc(cc(cc[nH]1)c1c1)c1F DANYGEQACAPBOK-UHFFFAOYSA-N 0.000 description 1
- HXIRJXFCXYDBKP-UHFFFAOYSA-N COc(cc(cc[n]1-c2ccccc2)c1c1)c1F Chemical compound COc(cc(cc[n]1-c2ccccc2)c1c1)c1F HXIRJXFCXYDBKP-UHFFFAOYSA-N 0.000 description 1
- WDWQIRDQRWWJNN-UHFFFAOYSA-N FC(c(cc1)ncc1-[n](ccc1c2)c1ccc2Br)(F)F Chemical compound FC(c(cc1)ncc1-[n](ccc1c2)c1ccc2Br)(F)F WDWQIRDQRWWJNN-UHFFFAOYSA-N 0.000 description 1
- YUGDKEWUYZXXRU-UHFFFAOYSA-N N#CCOc(cc1)ccc1Cl Chemical compound N#CCOc(cc1)ccc1Cl YUGDKEWUYZXXRU-UHFFFAOYSA-N 0.000 description 1
- RXNNHSKCCHGJQM-UHFFFAOYSA-N O=C(c(c(Cl)ncn1)c1Cl)Cl Chemical compound O=C(c(c(Cl)ncn1)c1Cl)Cl RXNNHSKCCHGJQM-UHFFFAOYSA-N 0.000 description 1
- GNPYGFCJTUDCEA-UHFFFAOYSA-N O=C(c(c(Cl)ncn1)c1OCC1)N1c(cc1cc2)cnc1[n]2-c1ccc(C(F)(F)F)cc1 Chemical compound O=C(c(c(Cl)ncn1)c1OCC1)N1c(cc1cc2)cnc1[n]2-c1ccc(C(F)(F)F)cc1 GNPYGFCJTUDCEA-UHFFFAOYSA-N 0.000 description 1
- DNXJXMKLAMLDCQ-UHFFFAOYSA-N OCCN(C(c(c(Cl)ncn1)c1Cl)=O)c(cc(cc[n]1-c2ccccc2)c1c1)c1F Chemical compound OCCN(C(c(c(Cl)ncn1)c1Cl)=O)c(cc(cc[n]1-c2ccccc2)c1c1)c1F DNXJXMKLAMLDCQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1452DE2011 | 2011-05-20 | ||
| IN1452/DEL/2011 | 2011-05-20 | ||
| US201161503728P | 2011-07-01 | 2011-07-01 | |
| US61/503,728 | 2011-07-01 | ||
| PCT/US2012/038523 WO2012162129A1 (en) | 2011-05-20 | 2012-05-18 | Novel compounds as diacylglycerol acyltransferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140045415A KR20140045415A (ko) | 2014-04-16 |
| KR101919080B1 true KR101919080B1 (ko) | 2018-11-16 |
Family
ID=47217645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137033509A Expired - Fee Related KR101919080B1 (ko) | 2011-05-20 | 2012-05-18 | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US8859536B2 (https=) |
| EP (1) | EP2710013B1 (https=) |
| JP (1) | JP5844456B2 (https=) |
| KR (1) | KR101919080B1 (https=) |
| CN (1) | CN103703009B (https=) |
| AU (1) | AU2012259044B2 (https=) |
| BR (1) | BR112013029935B1 (https=) |
| CA (1) | CA2836669C (https=) |
| CO (1) | CO6811855A2 (https=) |
| CR (1) | CR20130602A (https=) |
| CY (1) | CY1118188T1 (https=) |
| DK (1) | DK2710013T3 (https=) |
| DO (1) | DOP2013000272A (https=) |
| EA (1) | EA023030B1 (https=) |
| ES (1) | ES2588748T3 (https=) |
| HR (1) | HRP20161089T1 (https=) |
| HU (1) | HUE028870T2 (https=) |
| IL (1) | IL229488A (https=) |
| LT (1) | LT2710013T (https=) |
| MA (1) | MA35185B1 (https=) |
| ME (1) | ME02479B (https=) |
| MX (1) | MX346494B (https=) |
| MY (1) | MY184553A (https=) |
| PE (1) | PE20141204A1 (https=) |
| PH (1) | PH12013502401A1 (https=) |
| PL (1) | PL2710013T3 (https=) |
| PT (1) | PT2710013T (https=) |
| RS (1) | RS55006B1 (https=) |
| SG (1) | SG195044A1 (https=) |
| SI (1) | SI2710013T1 (https=) |
| SM (1) | SMT201600328B (https=) |
| UA (1) | UA111360C2 (https=) |
| WO (1) | WO2012162129A1 (https=) |
| ZA (1) | ZA201308664B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2836669C (en) | 2011-05-20 | 2019-03-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds as diacylglycerol acyltransferase inhibitors |
| WO2014081996A1 (en) * | 2012-11-23 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds as diacylglycerol acyltransferase inhibitors |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| EA031114B1 (ru) | 2012-11-23 | 2018-11-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ ДИГИДРОПИРИМИДО[5,4-f]ОКСАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ДИАЦИЛГЛИЦЕРИН АЦИЛТРАНСФЕРАЗЫ |
| CN103524431B (zh) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用 |
| WO2015049667A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| WO2015049668A1 (en) | 2013-10-03 | 2015-04-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel compound as a diacylglycerol acyltransferase inhibitor |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
| WO2016181409A1 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
| US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| CN105732461A (zh) * | 2016-02-03 | 2016-07-06 | 常州工程职业技术学院 | 5-甲氧基-6-卤代吲哚的制备方法 |
| CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
| CN107619928B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| CN107619932B (zh) * | 2016-07-15 | 2020-08-07 | 中国科学院上海有机化学研究所 | 一种萃取组合物、萃取体系及其应用 |
| RU2706655C1 (ru) * | 2019-01-28 | 2019-11-19 | Акционерное общество "Гознак" (АО "Гознак") | Полимерсодержащее композиционное защищенное изделие |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20100204119A1 (en) | 2009-02-02 | 2010-08-12 | Pfizer Inc | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives |
| US20100210622A1 (en) | 2008-12-19 | 2010-08-19 | Jonathan Bayldon Baell | Heterocyclic compounds and methods of use |
| US20100273768A1 (en) | 2009-04-24 | 2010-10-28 | Nolan James Dewdney | Inhibitors of Bruton's Tyrosine Kinase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010107768A1 (en) * | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| CA2836669C (en) | 2011-05-20 | 2019-03-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds as diacylglycerol acyltransferase inhibitors |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
-
2012
- 2012-05-18 CA CA2836669A patent/CA2836669C/en not_active Expired - Fee Related
- 2012-05-18 EA EA201391737A patent/EA023030B1/ru unknown
- 2012-05-18 EP EP12789931.8A patent/EP2710013B1/en active Active
- 2012-05-18 ES ES12789931.8T patent/ES2588748T3/es active Active
- 2012-05-18 MX MX2013013566A patent/MX346494B/es active IP Right Grant
- 2012-05-18 UA UAA201314878A patent/UA111360C2/uk unknown
- 2012-05-18 HR HRP20161089TT patent/HRP20161089T1/hr unknown
- 2012-05-18 PT PT127899318T patent/PT2710013T/pt unknown
- 2012-05-18 JP JP2014511575A patent/JP5844456B2/ja not_active Expired - Fee Related
- 2012-05-18 KR KR1020137033509A patent/KR101919080B1/ko not_active Expired - Fee Related
- 2012-05-18 ME MEP-2016-159A patent/ME02479B/me unknown
- 2012-05-18 HU HUE12789931A patent/HUE028870T2/en unknown
- 2012-05-18 MY MYPI2013702195A patent/MY184553A/en unknown
- 2012-05-18 PL PL12789931T patent/PL2710013T3/pl unknown
- 2012-05-18 DK DK12789931.8T patent/DK2710013T3/en active
- 2012-05-18 SG SG2013085501A patent/SG195044A1/en unknown
- 2012-05-18 US US14/118,976 patent/US8859536B2/en not_active Expired - Fee Related
- 2012-05-18 SI SI201230689A patent/SI2710013T1/sl unknown
- 2012-05-18 WO PCT/US2012/038523 patent/WO2012162129A1/en not_active Ceased
- 2012-05-18 PH PH1/2013/502401A patent/PH12013502401A1/en unknown
- 2012-05-18 RS RS20160648A patent/RS55006B1/sr unknown
- 2012-05-18 CN CN201280035792.5A patent/CN103703009B/zh not_active Expired - Fee Related
- 2012-05-18 AU AU2012259044A patent/AU2012259044B2/en not_active Ceased
- 2012-05-18 LT LTEP12789931.8T patent/LT2710013T/lt unknown
- 2012-05-18 BR BR112013029935-5A patent/BR112013029935B1/pt not_active IP Right Cessation
- 2012-05-18 PE PE2013002531A patent/PE20141204A1/es active IP Right Grant
-
2013
- 2013-11-18 IL IL229488A patent/IL229488A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08664A patent/ZA201308664B/en unknown
- 2013-11-20 CR CR20130602A patent/CR20130602A/es unknown
- 2013-11-20 CO CO13273126A patent/CO6811855A2/es active IP Right Grant
- 2013-11-20 DO DO2013000272A patent/DOP2013000272A/es unknown
- 2013-12-13 MA MA36566A patent/MA35185B1/fr unknown
-
2014
- 2014-09-05 US US14/478,309 patent/US9040517B2/en not_active Expired - Fee Related
-
2015
- 2015-04-24 US US14/695,206 patent/US9273069B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 US US14/996,318 patent/US9540400B2/en not_active Expired - Fee Related
- 2016-09-19 CY CY20161100926T patent/CY1118188T1/el unknown
- 2016-09-20 SM SM201600328T patent/SMT201600328B/it unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20100210622A1 (en) | 2008-12-19 | 2010-08-19 | Jonathan Bayldon Baell | Heterocyclic compounds and methods of use |
| US20100204119A1 (en) | 2009-02-02 | 2010-08-12 | Pfizer Inc | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives |
| US20100273768A1 (en) | 2009-04-24 | 2010-10-28 | Nolan James Dewdney | Inhibitors of Bruton's Tyrosine Kinase |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101919080B1 (ko) | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 | |
| AU2010315077B2 (en) | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | |
| KR101954044B1 (ko) | 피리돈 및 아자-피리돈 화합물 및 사용 방법 | |
| AU2017221865A1 (en) | Viral replication inhibitors | |
| CA2557541A1 (en) | Pyrimidine derivatives | |
| AU2013269800A1 (en) | Triazolo compounds as PDE10 inhibitors | |
| JP2021521142A (ja) | Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体 | |
| CN118139862A (zh) | 含氮杂环类化合物及其医药用途 | |
| US20250114345A1 (en) | Compounds and compositions as cbp/p300 degraders and uses thereof | |
| MXPA02005233A (es) | Pirazolo[1,5-d][1,2,4]triazinas para mejorar el conocimiento. | |
| KR102176463B1 (ko) | 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물 | |
| TWI915393B (zh) | 作為雄激素受體調節劑的吲哚化合物 | |
| HK1194738B (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| NZ617991B2 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-5-5-R10-R17-oth-X000 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20211110 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20211110 |